ReviewFrontiers in endocrinology2024
The role of multimodality imaging in diabetic cardiomyopathy: a brief review.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiac magnetic resonance biomarkers for cardiovascular complications in diabetes: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Article
- The Prognostic Impact of Cardiorespiratory Fitness on Mortality in Diabetes Patients With and Without Left Ventricular Hypertrophy.Reviews in cardiovascular medicine · 2026Article
- Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.Frontiers in endocrinology · 2026Article
- Advanced glycation end products and RAGE signaling in diabetic cardiomyopathy: distinct mechanisms, human evidence, and translational barriers.Frontiers in cardiovascular medicine · 2026Review
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- The Contribution of Echocardiography to the Diagnosis and Prognosis Stratification of Diabetic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2025Review
- [Advances in multimodal biomedical imaging of small animals].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025Review
- Deep phenotyping of a modified diabetic cardiomyopathy mouse model which reflects clinical disease progression.Diabetology & metabolic syndrome · 2025Article
- A comprehensive review on diabetic cardiomyopathy (DCM): histological spectrum, diagnosis, pathogenesis, and management with conventional treatments and natural compounds.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Predicting diabetic cardiomyopathy in type 2 diabetes: development and validation of a nomogram based on clinical and echocardiographic parameters.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DMCM), defined as left ventricular dysfunction in the setting of diabetes mellitus without hypertension, coronary artery disease or valvular heart disease, is a well-recognized entity whose prevalence is certainly predicted to increase alongside the rising incidence and prevalence of diabetes mellitus. The pathophysiology of DMCM stems from hyperglycemia and insulin resistance, resulting in oxidative stress, inflammation, cardiomyocyte death, and fibrosis. These perturbations lead to left ventricular hypertrophy with associated impaired relaxation early in the course of the disease, and eventually culminating in combined systolic and diastolic heart failure. Echocardiography, cardiac nuclear imaging, and cardiac magnetic resonance imaging are crucial in the diagnosis and management of the structural and functional changes associated with DMCM. There appears to be a U-shaped relationship between glycemic control and mortality. Exogenous insulin therapy, while crucial, has been identified as an independent risk factor for worsening cardiovascular outcomes. On the other hand, Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors appear to potentially offer glycemic control and cardiovascular protection. In this review, we briefly discuss the pathophysiology, staging, role of multimodality imaging, and therapeutics in DMCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.